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A changing landscape of
anticoagulation
Anticoagulation for stroke prevention in atrial fibrillation has tradition-
ally been performed by vitamin K antagonists. Although effective
under optimal conditions, the imminent risk of severe haemorrhage
is a major cause for substantial underutilization of these drugs, even
in patients at high risk of thrombo-embolic events. The recent intro-
duction of the direct thrombin inhibitor dabigatran, as well as the oral
factor Xa inhibitors rivaroxaban and apixaban (Figure 1) has resulted
in a paradigm shift regarding the treatment of these patients. While
large-scale clinical trials including Re-LY, ROCKET-AF, and ARIS-
TOTLE have (essentially) all indicated superiority of the respective
substance compared with warfarin in stroke prevention, these
agents were equally shown to be superior with respect to bleeding
events, especially major, life-threatening, and intracranial haemor-
rhage.1–3 The initial enthusiasm associated with these novel agents
was, however, dampened shortly after their introduction when
reports of major haemorrhages surfaced, indicating that an unre-
stricted and injudicious use may put certain patients at an elevated
risk for adverse events. Indeed, it quickly became clear that
especially dabigatran, which is 80% renally cleared, has a significant
potential for severe bleeding in patients with reduced renal function.
Anticoagulation in renal
insufficiency: caught between
the Scylla and Charybdis
Patients with renal insufficiency, however, are problematic for any
kind of anticoagulant treatment due to the increased risk for both
thrombo-embolic and bleeding events in this situation.4 A recent
cohort study once more identified reduced renal function as an in-
dependent predictor of cerebral ischaemic events, with a continu-
ous increase in risk with decreasing kidney function.5 This is even
further potentiated in patients with end-stage renal disease as
well as those on dialysis. In addition to the high prevalence of
co-morbidities predisposing for thrombo-embolic complications
such as hypertension, congestive heart failure, left atrial enlarge-
ment, and diabetes, the inflammatory state of chronic kidney
disease as well as alterations of blood constituents and endothelial
protein expression collectively result in a prothrombotic state.6 At
the same time, however, bleeding risk is equally increased in these
patients, probably due to poorly or non-functional platelets,
altered von Willebrand factor, and the presence of uraemic
toxins.4,6 As such, the treating physician is even more than normal-
ly caught between the Scylla and Charybdis when having to decide
whether or not—and if yes, how—to anticoagulate patients with
atrial fibrillation and renal insufficiency. With the rising incidence
and prevalence of both diseases, this scenario is encountered
with increasing frequency. Indeed, the co-prevalence of chronic
kidney disease and atrial fibrillation is reported to be as high as
20%, and is likely to increase even further.7 To make things even
more confusing, several studies have suggested that use of
vitamin K antagonists is even associated with an increased risk
for stroke in the extreme case of end-stage renal disease
patients.8,9
Apixaban in renal insufficiency
Hohnloser and colleagues have now reported the pre-specified
subgroup analysis of the ARISTOTLE trial for patients with
impaired renal function.10 In the overall trial, apixaban was asso-
ciated with a 22% reduction in stroke as well as a 31% reduction
in major bleeding.3 Importantly, a reduced dose of apixaban (2 ×
2.5 mg instead of the usual 2 × 5 mg) was given to patients with
two of the following criteria: age ≥ 80 years, weight ≤ 60 kg, and
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serum creatinine ≥ 133 mmol/L (1.5 mg/dL). Baseline creatinine
clearance was calculated according to the Cockcroft–Gault and
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equations as well as based on cystatin C measurements. When
compared with warfarin, apixaban was superior in reducing
stroke or systemic embolism, major bleeding, and mortality irre-
spective of kidney function. As already indicated in the primary
publication, apixaban was associated with less major bleeding
compared with warfarin across all categories of renal dysfunction,
but this reduction was significantly greater in patients with an esti-
mated glomerular filtration rate (eGFR) ≤ 50 mL/min (as deter-
mined by the Cockcroft–Gault equation of CKD-EPI, albeit not
when based on cystatin C eGFR). The reason for the inconsistent
effects with the (in practice much less frequently used) cystatin-
based eGFR calculation is not clear, but may be related to
confounding variables such as age. Importantly, the finding of a
statistically significant greater reduction in major bleeding in
patients with impaired renal function implies a particularly
pronounced benefit of apixaban compared with warfarin in this
patient population. Indeed, due to their iatrogenic nature, major
bleeding events are the single most prevalent reason why proper
anticoagulation is withheld in patients with atrial fibrillation,
especially those with impaired renal function.
Implications for daily clinical
practice
Should every patient with atrial fibrillation and renal insufficiency
hence be anticoagulated with apixaban? How does apixaban
compare with rivaroxaban and dabigatran in these patients? Unfor-
tunately, comprehensive cross-trial comparisons with the other
novel anticoagulants are impossible to perform given—among
others—the different study designs, different patient populations,
and (partly) different bleeding definitions. Since all three trials
compared the respective novel agent with warfarin, it would be
interesting to compare matched subsets of patients from each
trial; such data, however, are not yet available. Chronic kidney
disease certainly appears to be the ‘Achilles heel’ of dabigatran,
as accumulation is likely to occur due to mainly renal elimination.
Hence, in view of the available data, apixaban would probably be
the preferred agent over dabigatran in these patients. For rivarox-
aban, a solid and valid comparison is virtually impossible given the
above-mentioned limitations. Data from large registries and from
real-world use will provide additional evidence for further guid-
ance. For the time being, the current data with apixaban certainly
look very promising for patients with renal impairment.
The latter is particularly true for patients with moderately
reduce renal function. It should be kept in mind, however, that
only 1.5% of the included patients presented with an eGFR of ≤
30 mL/min, and patients with a creatinine clearance ,25 mL/min
or a serum creatinine .2.5 mg/dL (221 mmol/L) were a priori
excluded from the study.3 The amount of data to support the
use of apixaban in patients with severe renal insufficiency is
hence scarce. The problem, of course, in these patients is the
lack of alternatives, as vitamin K antagonist treatment is equally
problematic in this situation and subject to inherent limitations
and risks. Nevertheless, resorting to a familiar medication such
as the latter in the treatment of these particularly challenging
Figure 1. Point of action of novel oral anticoagulants in the coagulation cascade. See text for details. VKA, vitamin K antagonist. Adapted from
Steffel and Braunwald.
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patients is probably not the most unreasonable practice, especially
until some familiarization has occurred during treatment of the
many patients that otherwise qualify for apixaban. It should also
be kept in mind that the results of Hohnloser et al. are based on
baseline creatinine/GFR, whereas serial measurements are not pro-
vided. In contrast, in the real world and during longer treatment
periods, renal function frequently worsens over time, especially
in patients with various co-morbidities, necessitating individual
adaptation of risk assessment and therapies.
A key factor for the successful use of the novel anticoagulants is
their judicious application, especially in high-risk individuals. One of
the most important aspects in this regard is to withstand the temp-
tation to prescribe them in a ‘fill and forget’ manner, which is par-
ticularly true for patients with reduced renal function. As expected,
and consistent with previous studies, Hohnloser et al. found a gen-
erally increased risk for events in these patients (stroke, major
bleeding, all-cause mortality) as compared with those with
normal kidney function. Hence, physicians are likely to see more
events in their patients with renal dysfunction, independent of
the way they are treated, just by virtue of them being at high
risk for any kind of event. Data from the study of Hohnloser
et al. provide reassurance that patients with moderately reduced
renal function have a lower risk of major haemorrhage if treated
with apixaban as compared with warfarin. Nevertheless, also
with apixaban, regular follow-up of these high-risk patients, includ-
ing early detection of renal function deterioration and adaptation
of treatment, is crucial to successfully navigate between the
Scylla and Charybdis.
In summary, this substudy of the ARISTOTLE trial provides solid
evidence for the superiority of apixaban in patients with atrial fib-
rillation and chronic kidney disease. In the light of these data, apix-
aban appears to be a very appealing option for these individuals,
potentially leading to a substantial increase in the numbers of
appropriately anticoagulated patients. Judicious use and vigilant
follow-up will be key to fully exploit the benefits of this therapy.
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